SCHEDULE 13G/A: Frazier Life Sciences Funds Amend Trevi Therapeutics Stake
Beneficial Ownership Amendment
Frazier Life Sciences Public Fund and affiliates updated their beneficial ownership in Trevi Therapeutics, reporting a combined 7.0% stake.
Summary
- Frazier Life Sciences Public Fund, L.P. (FLSPF) and its related entities (FHMLSP, L.P. and FHMLSP, L.L.C.) beneficially own 8,508,021 shares of Trevi Therapeutics, Inc. common stock, representing 7.0% of the class.
- Frazier Life Sciences X, L.P. (FLS X) and its related entities (FHMLS X, L.P., FHMLS X, L.L.C., James N. Topper, and Patrick J. Heron) beneficially own 397,309 shares, representing 0.3% of the class.
- Frazier Life Sciences XI, L.P. (FLS XI) and its related entities (FHMLS XI, L.P. and FHMLS XI, L.L.C.) beneficially own 1,354,079 shares, representing 1.1% of the class.
- The percentages are calculated based on 121,776,855 shares of Common Stock outstanding on July 31, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed on August 7, 2025.
- The filing corrects previous attribution and overstatement of beneficial ownership by certain members of the investment committees for FLSPF and FLS XI.
- The reporting persons also hold prefunded warrants to acquire additional shares: FLSPF holds 10,331,265 warrants, FLS X holds 1,458,294 warrants, and FLS XI holds 2,459,389 warrants. All warrants are subject to a 9.99% beneficial ownership limitation upon exercise.
Sentiment
Score: 6
Explanation: The filing indicates continued significant institutional ownership by a specialized life sciences fund, which is generally positive. However, the correction of previous overstatements of beneficial ownership introduces a minor negative aspect related to reporting accuracy, though it doesn't reflect on the company's performance.
Positives
- Significant institutional ownership by Frazier Life Sciences, a specialized life sciences investor, indicates confidence in Trevi Therapeutics.
- The holding of prefunded warrants suggests potential for increased future investment, subject to beneficial ownership limitations.
Negatives
- The amendment corrects previous overstatements of beneficial ownership by certain individuals, which could imply past reporting inaccuracies.
Risks
- The beneficial ownership limitation on warrants (9.99%) restricts the immediate full exercise of these warrants, potentially limiting the investor's ability to increase their stake rapidly.
Future Outlook
The filing does not contain forward-looking statements or guidance regarding Trevi Therapeutics' operational or financial performance. It solely pertains to beneficial ownership disclosure.
Industry Context
Frazier Life Sciences is a prominent investor in the life sciences sector, and their continued significant stake in Trevi Therapeutics, a biotechnology company, aligns with their investment focus. This type of institutional ownership is common in the biotech industry, where specialized funds often take substantial positions in promising companies.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Beneficial Ownership Attribution Clarification | The filing clarifies that no members of the investment committees for FHMLSP, L.L.C. (general partner of FLSPF) and FHMLS XI, L.L.C. (general partner of FLS XI) are attributed beneficial ownership of the securities directly held by their respective funds. This corrects previous attribution and overstatement of beneficial ownership by such members. | 2025-09-30 | Improves accuracy of beneficial ownership reporting and clarifies the control structure within the Frazier Life Sciences entities regarding Trevi Therapeutics shares. |
Stakeholder Impact
- Shareholders: Provides transparency regarding significant institutional ownership and potential future share issuance through warrant exercise. The clarification of beneficial ownership attribution enhances reporting accuracy.
- Company Management: Awareness of a significant, specialized institutional investor with a long-term interest, potentially influencing strategic decisions or providing stability.
Key Dates
| Date | Description |
|---|---|
| 2017-07-31 | Date Power of Attorney for James N. Topper and Patrick J. Heron was filed with the SEC. |
| 2021-08-16 | Date Power of Attorney for Albert Cha and James Brush was filed with the SEC. |
| 2022-04-18 | Date Power of Attorney for Daniel Estes was filed with the SEC. |
| 2025-05-15 | Date of Joint Filing Agreement incorporated by reference into this Statement. |
| 2025-07-31 | Date for which 121,776,855 shares of Common Stock outstanding were reported in the Issuer's 10-Q. |
| 2025-08-07 | Date Issuer's Quarterly Report on Form 10-Q was filed with the SEC. |
| 2025-09-30 | Date of event requiring the filing of this Schedule 13G Amendment No. 5. |
| 2025-11-14 | Date of signing for the Schedule 13G Amendment No. 5. |
Recommendation
holdThis Schedule 13G filing is a routine disclosure of beneficial ownership by Frazier Life Sciences funds in Trevi Therapeutics. It confirms a substantial, albeit slightly adjusted, institutional stake and the existence of significant warrants. While the correction of prior attribution is noted, it does not fundamentally alter the investment thesis or the company's operational outlook. The filing provides no new information that would warrant a change in investment strategy, thus a 'hold' recommendation is appropriate for existing investors, and 'na' for new investors as it doesn't provide enough information for a new investment decision.
Keywords
Trevi Therapeutics, Frazier Life Sciences, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Biotechnology, Life Sciences, SEC Filing, Warrants
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.